Aminobol 5% 250 ml Solution

Aminobol, 5% infusion solution

Aminobol composition

The 250 ml volume of the Aminobol preparation contains the following components: L-proline 250 mg, L-serine 250 mg, L-alanine 500 mg, L-isoleucine 880 mg, L-leucine 1225 mg, L-aspartic acid 625 mg, L-tyrosine 62.5 mg, L-glutamic acid 187.5 mg, L-phenylalanine 1332.5 mg, L-arginine hydrochloride 1250 mg, L-lysine hydrochloride 1075 mg, L-valine 900 mg, L-threonine 625 mg, L-histidine hydrochloride 625 mg, L-tryptophan 225 mg, L-methionine 562.5 mg, L-cysteine 25 mg and glycine 1900 mg.

The 500 ml volume of the Aminobol preparation contains the following components: L-proline 500 mg, L-serine 500 mg, L-alanine 1000 mg, L-isoleucine 1760 mg, L-leucine 2450 mg, L-aspartic acid 1250 mg, L-tyrosine 125 mg, L-glutamic acid 375 mg, L-phenylalanine 2665 mg, L-arginine hydrochloride 2500 mg, L-lysine hydrochloride 2150 mg, L-valine 1800 mg, L-threonine 1250 mg, L-histidine hydrochloride 1250 mg, L-tryptophan 450 mg, L-methionine 1125 mg, L-cysteine 50 mg and glycine 3800 mg.

Contraindications

The use of the preparation is contraindicated in patients with severe liver failure, severe kidney failure/metabolic disorders of amino acids. This preparation is not recommended for use in patients with severe acidosis and
heart failure with hyperemia.

Directions for use and dosage

It is used as an infusion in drops (fleboclysis). The total dose for adults is as follows: When administered by infusion, it is given 4 times a day, 250–500 ml each time, at a rate of
40–50 drops/min.
Children, elderly patients, and patients with a weak body and those with serious illnesses should follow the doctor’s
instructions. For sufficient use of amino acids and the presence of protein, to ensure the necessary energy, glucose, and an appropriate amount of electrolytes, vitamins, and microelements.
CAUTION
1 – The use of the preparation is prohibited in patients who have had a coma of the brain or are prone to it.
2 – The use of the preparation is prohibited in patients with severe renal failure and uremia.
3 – The use of the preparation is prohibited in patients with metabolic disorders of amino acids.
4 – The rate of intravenous administration must be very slow; otherwise nausea, vomiting, fever, and headache may occur; it may also lead to thrombotic phlebitis.
5 – Do not use the preparation if any of the following occurs: cloudiness, loss of the cap,
slight cracks in the vials, etc.
6 – NaHSO3 contained in the preparation may sometimes cause allergic reactions.